Skip to main content

Artificial Intelligence/Machine Learning Consortium (AI/ML Consortium)

The AI/ML Consortium was established in 2021 to support the application of cognitive systems to the vast genetic, imaging, biomarker, and clinical data generated by ADSP and other NIA-funded initiatives. The collection of projects funded through the Consortium use artificial intelligence and machine learning approaches to achieve a number of goals, including, but not limited to, advancing gene discovery, modeling variant/gene action, building prognostic models based on biomarkers, and identifying opportunities for drug repurposing.

Funded AI/ML Projects

Alzheimer’s MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics Discovery (U01AG073323)

  • MPIs: Feixiong Cheng, Lynn M. Bekris, and James B. Leverenz

Cognitive Computing of Alzheimer’s Disease Genes and Risk (U01AG068214)

  • PI: Olivier Lichtarge

Assessing Alzheimer Disease Risk and Heterogeneity Using Multimodal Machine Learning Approaches (U01AG068221)

  • MPIs: Honghuang Lin and Anita L. DeStefano

Artificial Intelligence Strategies for Alzheimer’s Disease Research (U01AG066833)

  • MPIs: Jason Moore, Marylyn Ritchie, and Li Shen

Causal and integrative deep learning for Alzheimer’s disease genetics (U01AG073079)

  • PI: Wei Pan

Learning the Regulatory Code of Alzheimer’s Disease Genomes (U01AG068880)

  • MPIs: Towfique Raj and David A. Knowles

Ultrascale Machine Learning to Empower Discovery in Alzheimer’s Disease Biobanks (U01AG068057)

  • MPIs: Paul M. Thompson, Christos Davatzikos, Heng Huang, Andrew J. Saykin, and Li Shen

Genetics of Deep-Learning-Derived Neuroimaging Endophenotypes for Alzheimer’s Disease (U01AG070112)

  • MPIs: Degui Zhi, Myriam Fornage, and Shuiwang Ji

Associated Groups

The ADSP AI/ML Consortium is applying cognitive systems approaches to the analysis of AD genetic and related data. Analysis of the data generated and harmonized by the ADSP will help to identify new genes and genetic pathways that will reveal risk and protective factors for AD and guide the field toward novel therapeutic approaches to the disease. The AI/ML Working Group meets to share research updates.

The AI/ML Executive Committee comprises the AI/ML Consortium MPIs and NIA program officers. They meet to discuss administrative topics for the Consortium.